All In Biotech

Drug Trial Radar · NCT03793478

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination With Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) With FLT3-ITD Mutations

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Aug 15, 2018

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Innovative Therapies For Children with Cancer Consortium; Children's Oncology Group
First posted
Jan 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • QuizartinibDrug

    Administered orally once daily starting on Day 6 and continuing through Day 28; Optional low intensity consolidation with chemotherapy: Administered orally once daily starting on Day 1 and continuing through Day 28

  • FludarabineDrug

    30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)

  • CytarabineDrug

    2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care); Optional high intensity consolidation with chemotherapy and quizartinib: 500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4; Optional low intensity consolidation with chemotherapy: 75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18

  • Intrathecal (IT) triple chemotherapy prophylaxisDrug

    IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site

  • EtoposideDrug

    Optional high intensity consolidation with chemotherapy and quizartinib: 100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of dose-limiting toxicities (Phase 1)Time frame: Re-induction Cycle 1 Day 1 up to Day 28 (each cycle is 28 days)
  2. Composite complete remission (CRc) rate among participants with acute myeloid leukemia (AML) (Phase 1 and 2)Time frame: within 8 years, 8 months
  3. Pharmacokinetic parameter area under the concentration curve for quizartinib and AC886 (Phase 1 and 2)Time frame: Re-induction Phase 1 and 2,Cycle 1: Days 6, 20:Predose, 1 hour (Phase 1 only), 2, 4, and 6 hours; Days 7 and 21:24 hours; Phase 1 and 2 Cycle 2: Days 6 and 20:predose, 3 hours; Continuation Cycle 1 Days 1 and 15:predose, 2-4 hours (each cycle, 28 days)
  4. Pharmacokinetic parameter apparent clearance (CL/F) for quizartinib and AC886 (Phase 1 and 2)Time frame: Re-induction Phase 1 and 2,Cycle 1: Days 6, 20:Predose, 1 hour (Phase 1 only), 2, 4, and 6 hours; Days 7 and 21:24 hours; Phase 1 and 2 Cycle 2: Days 6 and 20:predose, 3 hours; Continuation Cycle 1 Days 1 and 15:predose, 2-4 hours (each cycle, 28 days)
  5. Pharmacokinetic parameter apparent volume of distribution (Vz/F) for quizartinib and AC886 (Phase 1 and 2)Time frame: Re-induction Phase 1 and 2,Cycle 1: Days 6, 20:Predose, 1 hour (Phase 1 only), 2, 4, and 6 hours; Days 7 and 21:24 hours; Phase 1 and 2 Cycle 2: Days 6 and 20:predose, 3 hours; Continuation Cycle 1 Days 1 and 15:predose, 2-4 hours (each cycle, 28 days)

Locations

27 sites in 10 countries. Site status is shown where the registry gives one.

  • Loma Linda University Cancer Center

    Loma Linda, California

  • University of California, San Francisco

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • A.I. duPont Hospital for Children

    Wilmington, Delaware

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • University of Minnesota/Masonic Cancer Center

    Minneapolis, Minnesota

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • The University of Texas Southwestern Medical Center Children's Health

    Dallas, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • British Columbia Children's Hospital

    Vancouver, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Rigshospitalet

    Copenhagen, Denmark

  • Centre Léon Bérard

    Lyon, France

  • Hôpital Armand-Trousseau

    Paris, France

  • Hôpital des Enfants

    Toulouse, France

  • Rambam Medical Center

    Haifa, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Italy

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Rome, Italy

  • Ospedale Infantile Regina Margherita

    Torino, Italy

  • Prinses Maxima Centrum voor Kinderoncologie

    Utrecht, Netherlands

  • Hospital Infantil Universitario Nino Jesus

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Sahlgrenska Universitetssjukhuset - Drottning Silvias Barn- och Ungdomssjukhus

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.